Every 8-K that Actinium Pharmaceuticals, Inc (ATNM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ATNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATNM filings page.
Actinium Pharmaceuticals, Inc. reports that NYSE Regulation has accepted its compliance plan, granting a plan period through November 27, 2027 to regain compliance with NYSE American continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii). During this period, the common stock will continue to trade on NYSE American under the symbol ATNM, subject to ongoing compliance with other listing requirements and periodic NYSE review. Failure to regain compliance or demonstrate satisfactory progress may lead to delisting proceedings.
Actinium also highlights advances in its Actimab-A radiotherapy program, including multiple newly issued and allowed patents in the United States and internationally, with terms extending into 2037–2043, covering uses in AML, MDS and solid tumors via myeloid-derived suppressor cell targeting. The company has amended its IND to add an additional manufacturer to support studies under its CRADA with the National Cancer Institute and company-sponsored trials, aiming to expand manufacturing capacity as clinical milestones approach from late 2026 into 2027. Actinium states it has about 250 patents and patent applications across its portfolio.
Actinium Pharmaceuticals, Inc. has submitted a compliance plan to NYSE American after being notified it is not meeting certain continued listing standards. The exchange requires stockholders’ equity of at least $4.0 million when a company has recorded losses in three of its four most recent fiscal years.
The plan outlines actions management intends to take to restore compliance and maintain the company’s NYSE American listing status. The filing does not detail the specific steps but confirms the plan was delivered on June 18, 2026, in response to the prior deficiency notice.
Actinium Pharmaceuticals received a notice from NYSE American that it is not in compliance with continued listing standards because its stockholders’ equity was approximately $2.3 million as of March 31, 2026, below the required $4.0 million minimum and after reporting net losses in its last five fiscal years. The company must submit a plan by June 26, 2026 to regain compliance by November 27, 2027, or it may face delisting, though its shares will continue trading on NYSE American under the symbol ATNM with a “.BC” below-compliance indicator. Actinium intends to submit a plan and, separately, plans to present new preclinical data for its ATNM-400 radioconjugate program and related pipeline candidates at the SNMMI 2026 conference.
Actinium Pharmaceuticals, Inc. filed an amendment to update its prior report on the results of its Annual General Meeting. Shareholders had indicated a preference for holding an advisory vote on executive compensation (“Say-on-Pay”) every year.
On March 20, 2026, the board of directors decided that future Say-on-Pay votes will be conducted annually, aligning with the shareholder preference. The board plans to re-evaluate this approach after the next shareholder advisory vote on Say-on-Pay frequency, which is expected at the 2031 Annual General Meeting of Shareholders, unless considered earlier.
Actinium Pharmaceuticals reported a leadership change in its finance function. Chief Financial Officer Steve O’Loughlin has resigned, effective February 27, 2026, to pursue other opportunities. The company states there were no disagreements that contributed to his decision.
To fill the principal financial officer role, the Board appointed Sandesh Seth, the current Chairman and Chief Executive Officer, effective as of the same date. Seth has led the company as CEO since 2017, has served on the Board since 2012, and brings more than 25 years of experience in investment banking, equity research, and the pharmaceutical industry. The filing notes there are no disclosable family relationships or related-party transactions involving him.
Actinium Pharmaceuticals, Inc. reported the final results of its 2025 annual meeting of stockholders. Stockholders re-elected Class III directors Ajit S. Shetty and June S. Almenoff to serve until the 2028 annual meeting. Mr. Shetty received 5,032,369 votes for and 1,234,852 withheld, while Dr. Almenoff received 5,284,503 votes for and 982,719 withheld, with 9,354,877 broker non-votes for each.
A total of 15,494,573 shares were present in person or by proxy out of 31,195,891 shares of common stock outstanding as of the October 15, 2025 record date. Stockholders approved all proposals, including, on a non-binding basis, the compensation of named executive officers (4,481,875 for, 1,541,460 against, 243,885 abstain, and 9,354,877 broker non-votes) and three years as the frequency for future advisory votes on executive pay.